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Background: Patients with sickle cell disease (SCD) have a high
risk of intracranial large vessel vasculopathy. This can lead to
a proliferation of microvasculature at the base of the brain known
as moyamoya syndrome. If untreated, there is a high risk of intra-
ventricular hemorrhage and permanent neurologic deficits. There
have been several reports describing patients with SCD and
moyamoya syndrome successfully undergoing revascularization
procedures, including encephaloduroarteriosynangiosis (EDAS).
Hematopoietic cell transplantation from a compatible sibling is
the most effective way of preventing central nervous system
(CNS) complications in SCD patients at risk for CNS events.
To our knowledge, there have been no reports of SCD patients
undergoing EDAS followed by bone marrow transplantation
(BMT).
Case:We describe the case of a 14-year-old girl with SCD who de-
veloped severe stenosis of the right internal carotid artery, which
progressed and extended to the anterior cerebral andmiddle cerebral
arteries, with silent infarcts and changes on magnetic resonance an-
giography (MRA) consistent with moyamoya syndrome. Due to
worsening of her stenosis, at the age of 11 she underwent EDAS
without complications. Eighteenmonths after the procedure, she de-
veloped a left lower extremity monoparesis. Magnetic resonance im-
aging (MRI) did not show any new areas of ischemia. Three months
later she underwent high-dose chemo-immunotherapy followed by
BMT from her compatible sibling. Her mixed-donor chimerism
on day +32 was 98% donor, with concomitant hemoglobin S of
0.9%, confirming donor engraftment and eradication of her SCD.
The patient is now 10 months post-transplant and has not had any
SCD-related complications. Her neurologic exam and neuroimag-
ing studies remain stable.
Conclusion: This is the first case report of EDAS successfully fol-
lowed by BMT in a patient with SCD and moyamoya syndrome.
BMT is considered standard of care in patients with SCD at risk
for CNS complications, leading to stroke-free survival rates of 93-
96%. Patients with moyamoya syndrome and SCD who have
a CNS event are more than twice as likely to experience a recurrent
CNS complication even while on chronic transfusions. Transplant-
eligible SCDpatients who developmoyamoya syndromemay benefit
from EDAS prior to undergoing BMT in order to minimize peri-
and post-transplant CNS complications. Further investigation is
needed to determine the long-term outcome of this therapeutic com-
bination.317
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Introduction: Hemorrhagic cystitis (HC) is a common complica-
tion after haematopoietic stem cell transplantation (HSCT).
Urotropic viruses may cause late-onset HC (BK virus {BKV}, adeno-virus, CMV) associated with severe immunosuppression. Treatment
is mainly symptomatic. The incidence and severity of HC depends
on primary disease, pre-transplant viral status, conditioning, immu-
nosuppressive drugs, source of graft and Graft-versus-Host Disease.
Objectives:: to review the incidence, severity, treatment and
outcome of BKV associated HC post HSCT.
Methods: Patients with BKV associated HC were identified retro-
spectively, reviewing electronic charts of all hospitalized children
in 2004-2010. Diagnosis of BKV is made by a standard Blood and
urine PCR method.
Results: BKV associated HC developed in 11children, during the
study period. One patient had primary immune deficiency and
lymphoma. There were 42 patients with autologous BMT, none
of them had HC. In 10/81 (12%) HC developed after allogeneic
HSCT. Nine patients received Antithymoglobulin (ATG) in com-
bination with high dose of Cyclophosphamide, steroids or total
body irradiation and developed symptoms of HC in the first 3
months after BMT. In 5/10 children Blood CMV reactivation oc-
curred concomitantly. The last 3 patients were treated with low
dose cidofovir (1mg/kg) weekly and 1 patient received a combina-
tion of parenteral and intravesicular cidofovir with an excellent ef-
fect consisting of rapid clinical recovery after 2 doses and
significant decreasing of BK viral load in blood and urine without
side effects. The improvement was more prominent with tapering
down of immune suppressive medications and immune reconstitu-
tion after HSCT.
Conclusion:BKHC is a severe complication after allogeneicHSCT
children. ATG combined with TBI or Cyclophosphamide is a signif-
icant risk factor. Low dose cidofovir could be the option for the treat-
ment of BK infection in combination with symptomatic treatment
until immunological recovery after HSCT.318
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Reduced-intensity conditioning (RIC) regimens have extended
the availability of allogeneic hematopoietic cell transplantation
(HCT) to a large group of previously ineligible adult patients with
hematological malignancies. To address whether this is a feasible ap-
proach for secondHCT in children with relapsed acute myeloid leu-
kemia (AML) following allogeneic HCT, we evaluated outcomes of
patients with AML transplanted using RIC at our center, between
2005-2010.
Nine out of total 10 patients with relapsed AML following al-
logeneic HCT were in CR2 or higher disease status at the time
of second HCT (table). Type of grafts included bone marrow
(5), peripheral blood stem cells (1), and umbilical cord blood
(4), that were obtained from matched unrelated donors in 9 pa-
tients and matched sibling donor in 1. All patients received RIC
containing Fludarabine 25mg/m2 from day-8 through Day-4
and Melphalan 140mg/m2 on day -3. One patient with baseline
chromosomal sensitivity was transplanted in CR1, with 50% re-
duction in Melphalan dose (70mg/m2). Graft versus host disease
(GVHD) prophylaxis included cyclosporine (CSA) and Mycophe-
nolate mofetil (MMF) in 7 patients, CSA with steroids in 1 and
tacrolimus with MMF in remaining 2 patients.
All 10 patients tolerated the RIC well without any major compli-
cations or organ dysfunction. All achieved sustained neutrophil en-
graftment, and 9/10 achieved platelet engraftment. Serious
infections included Candida fungemia (2 patients), that responded
well to antifungal therapy. At a median follow-up of 41.4 months
(range 2.5-56.3), 5 patients are alive, and remain disease free, includ-
ing all 4 patients who developedGVHD (Table) and the patient with
underlying chromosomal sensitivity. Of note, 3 of these patients have
